{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:47:08Z","timestamp":1789757228967,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.thromres.2017.05.029","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T19:16:08Z","timestamp":1496171768000},"page":"46-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome"],"prefix":"10.1016","volume":"157","author":[{"given":"L.","family":"Jeraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Jezovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Poredos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.thromres.2017.05.029_bb0005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2017.05.029_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11886-013-0463-2","article-title":"Current state of anticoagulants to treat deep venous thrombosis","volume":"16","author":"Vo","year":"2014","journal-title":"Curr Cardiol Rep."},{"issue":"26","key":"10.1016\/j.thromres.2017.05.029_bb0015","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2017.05.029_bb0020","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2012.04806.x","article-title":"Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?","volume":"10","author":"Baglin","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2017.05.029_bb0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.05.029_bb0030","article-title":"Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome","volume":"24","author":"Villalta","year":"1994","journal-title":"Haemostasis"},{"issue":"5","key":"10.1016\/j.thromres.2017.05.029_bb0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2017.05.029_bb0040","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2017.05.029_bb0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjmed.2011.02.033","article-title":"Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review","volume":"124","author":"Hull","year":"2011","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2017.05.029_bb0050","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-149-10-200811180-00004","article-title":"Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis","volume":"149","author":"Kahn","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2017.05.029_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2011.01733.x","article-title":"Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants","volume":"88","author":"Prandoni","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2017.05.029_bb0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12325-014-0119-7","article-title":"Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results","volume":"31","author":"Cohen","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2017.05.029_bb0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","article-title":"Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis","volume":"144","author":"Terry","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.05.029_bb0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2017.05.029_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11739-016-1411-0","article-title":"Why switch from warfarin to NOACs?","volume":"11","author":"Verdecchia","year":"2016","journal-title":"Intern. Emerg. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481730347X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481730347X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T05:26:25Z","timestamp":1535779585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481730347X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":15,"alternative-id":["S004938481730347X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2017.05.029","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2017.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}